461 related articles for article (PubMed ID: 19453367)
1. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival.
Krick EL; Billings AP; Shofer FS; Watanabe S; Sorenmo KU
Vet Comp Oncol; 2009 Jun; 7(2):130-8. PubMed ID: 19453367
[TBL] [Abstract][Full Text] [Related]
2. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
Taylor F; Gear R; Hoather T; Dobson J
J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
[TBL] [Abstract][Full Text] [Related]
3. Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis.
Weishaar KM; Thamm DH; Worley DR; Kamstock DA
J Comp Pathol; 2014 Nov; 151(4):329-38. PubMed ID: 25172053
[TBL] [Abstract][Full Text] [Related]
4. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007).
Hume CT; Kiupel M; Rigatti L; Shofer FS; Skorupski KA; Sorenmo KU
J Am Anim Hosp Assoc; 2011; 47(1):37-44. PubMed ID: 21164163
[TBL] [Abstract][Full Text] [Related]
6. A review of sentinel lymph node evaluation and the need for its incorporation into veterinary oncology.
Tuohy JL; Milgram J; Worley DR; Dernell WS
Vet Comp Oncol; 2009 Jun; 7(2):81-91. PubMed ID: 19453362
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia.
Litster AL; Sorenmo KU
J Feline Med Surg; 2006 Jun; 8(3):177-83. PubMed ID: 16476559
[TBL] [Abstract][Full Text] [Related]
8. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours.
Murphy S; Sparkes AH; Blunden AS; Brearley MJ; Smith KC
Vet Rec; 2006 Mar; 158(9):287-91. PubMed ID: 16517820
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures.
Worley DR
Vet Comp Oncol; 2014 Sep; 12(3):215-26. PubMed ID: 22958227
[TBL] [Abstract][Full Text] [Related]
11. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs.
Schultheiss PC; Gardiner DW; Rao S; Olea-Popelka F; Tuohy JL
J Am Vet Med Assoc; 2011 Jun; 238(11):1464-9. PubMed ID: 21627510
[TBL] [Abstract][Full Text] [Related]
12. Lymph node histology for the assessment of residual neoplastic disease in canine mast cell tumours: does the presence of metachromatic granules always identify mast cells?
Ressel L; Finotello R
Vet Comp Oncol; 2017 Dec; 15(4):1119-1121. PubMed ID: 27714908
[No Abstract] [Full Text] [Related]
13. Evaluation of prognostic factors for dogs with primary lung tumors: 67 cases (1985-1992).
McNiel EA; Ogilvie GK; Powers BE; Hutchison JM; Salman MD; Withrow SJ
J Am Vet Med Assoc; 1997 Dec; 211(11):1422-7. PubMed ID: 9394893
[TBL] [Abstract][Full Text] [Related]
14. Use of indirect computed tomography lymphangiography to determine metastatic status of sentinel lymph nodes in dogs with a pre-operative diagnosis of melanoma or mast cell tumour.
Grimes JA; Secrest SA; Wallace ML; Laver T; Schmiedt CW
Vet Comp Oncol; 2020 Dec; 18(4):818-824. PubMed ID: 32216019
[TBL] [Abstract][Full Text] [Related]
15. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs.
Dobson JM; Scase TJ
J Small Anim Pract; 2007 Aug; 48(8):424-31. PubMed ID: 17559522
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs.
Abadie JJ; Amardeilh MA; Delverdier ME
J Am Vet Med Assoc; 1999 Dec; 215(11):1629-34. PubMed ID: 14567425
[TBL] [Abstract][Full Text] [Related]
17. Surgical approach for lymph node staging of oral and maxillofacial neoplasms in dogs.
Smith MM
J Vet Dent; 2002 Sep; 19(3):170-4. PubMed ID: 12382534
[No Abstract] [Full Text] [Related]
18. Nucleomorphometric analysis of canine cutaneous mast cell tumours.
Maiolino P; Cataldi M; Paciello O; Restucci B; De Vico G
J Comp Pathol; 2005; 133(2-3):209-11. PubMed ID: 16045919
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
Hahn KA; Legendre AM; Shaw NG; Phillips B; Ogilvie GK; Prescott DM; Atwater SW; Carreras JK; Lana SE; Ladue T; Rusk A; Kinet JP; Dubreuil P; Moussy A; Hermine O
Am J Vet Res; 2010 Nov; 71(11):1354-61. PubMed ID: 21034327
[TBL] [Abstract][Full Text] [Related]
20. Histologically low-grade, yet biologically high-grade, canine cutaneous mast cell tumours: A systematic review and meta-analysis of individual participant data.
Bae S; Milovancev M; Bartels C; Irvin VL; Tuohy JL; Townsend KL; Leeper H
Vet Comp Oncol; 2020 Dec; 18(4):580-589. PubMed ID: 32103587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
